Cargando…

High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer

BACKGROUND: High dose-rate Intra-Operative Radiation Therapy (HD-IORT) is used to provide effective local control for patients with high-risk locally advanced or recurrent tumors. However, the utility of HD-IORT for patients with bladder cancer has not been studied. OBJECTIVE: To characterize our in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kates, Max, Chappidi, Meera R., Brant, Aaron, Milbar, Niv, Sopko, Nikolai A., Meyer, Christian, Terezakis, Stephanie A., Herman, Joseph M., Efron, Jonathan E., Safar, Bashar, Tran, Phuoc T., Ahuja, Nita, Pierorazio, Phillip M., Bivalacqua, Trinity J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545919/
https://www.ncbi.nlm.nih.gov/pubmed/28824947
http://dx.doi.org/10.3233/BLC-170104
_version_ 1783255505990320128
author Kates, Max
Chappidi, Meera R.
Brant, Aaron
Milbar, Niv
Sopko, Nikolai A.
Meyer, Christian
Terezakis, Stephanie A.
Herman, Joseph M.
Efron, Jonathan E.
Safar, Bashar
Tran, Phuoc T.
Ahuja, Nita
Pierorazio, Phillip M.
Bivalacqua, Trinity J.
author_facet Kates, Max
Chappidi, Meera R.
Brant, Aaron
Milbar, Niv
Sopko, Nikolai A.
Meyer, Christian
Terezakis, Stephanie A.
Herman, Joseph M.
Efron, Jonathan E.
Safar, Bashar
Tran, Phuoc T.
Ahuja, Nita
Pierorazio, Phillip M.
Bivalacqua, Trinity J.
author_sort Kates, Max
collection PubMed
description BACKGROUND: High dose-rate Intra-Operative Radiation Therapy (HD-IORT) is used to provide effective local control for patients with high-risk locally advanced or recurrent tumors. However, the utility of HD-IORT for patients with bladder cancer has not been studied. OBJECTIVE: To characterize our institutional experience with HD-IORT in patients with cancer requiring genitourinary surgery, in an effort to identify patients with bladder cancer that may benefit from HD-IORT. METHODS: We performed a retrospective review of all patients who have undergone HD-IORT during genitourinary surgery at our institution. Patients were stratified by surgical margin status, and primary outcomes assessed were overall survival, recurrence free survival and 90-day complications. Patients undergoing cystectomy and HD-IORT with sarcomatoid urothelial cancer were compared to a similar cohort undergoing cystectomy alone. A sample case of one such patient is discussed in detail. RESULTS: 84 patients at our institution have undergone HD-IORT with genitourinary surgery. Positive surgical margin status was the greatest predictor of both OS (HR = 3.42) and RFS (HR = 2.61). The overall 90-day complication rate was 61%, with wound infections (43%) and GI complications (21%) being most common. 4 of these patients had sarcomatoid urothelial histology, and all are still alive with >2 yrs follow up. This compares to a 52% 1 yr survival in our sarcomatoid urothelial cohort (25 pts) that did not undergo HD-IORT. CONCLUSIONS: Our institutional experience with HD-IORT has been promising, particularly among patients with locally advanced disease and sarcomatoid histology. We are currently enrolling patients in a multi-institutional registry to assess the utility of HD-IORT in high risk bladder cancer.
format Online
Article
Text
id pubmed-5545919
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-55459192017-08-16 High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer Kates, Max Chappidi, Meera R. Brant, Aaron Milbar, Niv Sopko, Nikolai A. Meyer, Christian Terezakis, Stephanie A. Herman, Joseph M. Efron, Jonathan E. Safar, Bashar Tran, Phuoc T. Ahuja, Nita Pierorazio, Phillip M. Bivalacqua, Trinity J. Bladder Cancer Research Report BACKGROUND: High dose-rate Intra-Operative Radiation Therapy (HD-IORT) is used to provide effective local control for patients with high-risk locally advanced or recurrent tumors. However, the utility of HD-IORT for patients with bladder cancer has not been studied. OBJECTIVE: To characterize our institutional experience with HD-IORT in patients with cancer requiring genitourinary surgery, in an effort to identify patients with bladder cancer that may benefit from HD-IORT. METHODS: We performed a retrospective review of all patients who have undergone HD-IORT during genitourinary surgery at our institution. Patients were stratified by surgical margin status, and primary outcomes assessed were overall survival, recurrence free survival and 90-day complications. Patients undergoing cystectomy and HD-IORT with sarcomatoid urothelial cancer were compared to a similar cohort undergoing cystectomy alone. A sample case of one such patient is discussed in detail. RESULTS: 84 patients at our institution have undergone HD-IORT with genitourinary surgery. Positive surgical margin status was the greatest predictor of both OS (HR = 3.42) and RFS (HR = 2.61). The overall 90-day complication rate was 61%, with wound infections (43%) and GI complications (21%) being most common. 4 of these patients had sarcomatoid urothelial histology, and all are still alive with >2 yrs follow up. This compares to a 52% 1 yr survival in our sarcomatoid urothelial cohort (25 pts) that did not undergo HD-IORT. CONCLUSIONS: Our institutional experience with HD-IORT has been promising, particularly among patients with locally advanced disease and sarcomatoid histology. We are currently enrolling patients in a multi-institutional registry to assess the utility of HD-IORT in high risk bladder cancer. IOS Press 2017-07-27 /pmc/articles/PMC5545919/ /pubmed/28824947 http://dx.doi.org/10.3233/BLC-170104 Text en © 2017 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Report
Kates, Max
Chappidi, Meera R.
Brant, Aaron
Milbar, Niv
Sopko, Nikolai A.
Meyer, Christian
Terezakis, Stephanie A.
Herman, Joseph M.
Efron, Jonathan E.
Safar, Bashar
Tran, Phuoc T.
Ahuja, Nita
Pierorazio, Phillip M.
Bivalacqua, Trinity J.
High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer
title High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer
title_full High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer
title_fullStr High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer
title_full_unstemmed High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer
title_short High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer
title_sort high dose-rate intra-operative radiation therapy during high risk genitourinary surgery: initial observations and a proposal for its study in bladder cancer
topic Research Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545919/
https://www.ncbi.nlm.nih.gov/pubmed/28824947
http://dx.doi.org/10.3233/BLC-170104
work_keys_str_mv AT katesmax highdoserateintraoperativeradiationtherapyduringhighriskgenitourinarysurgeryinitialobservationsandaproposalforitsstudyinbladdercancer
AT chappidimeerar highdoserateintraoperativeradiationtherapyduringhighriskgenitourinarysurgeryinitialobservationsandaproposalforitsstudyinbladdercancer
AT brantaaron highdoserateintraoperativeradiationtherapyduringhighriskgenitourinarysurgeryinitialobservationsandaproposalforitsstudyinbladdercancer
AT milbarniv highdoserateintraoperativeradiationtherapyduringhighriskgenitourinarysurgeryinitialobservationsandaproposalforitsstudyinbladdercancer
AT sopkonikolaia highdoserateintraoperativeradiationtherapyduringhighriskgenitourinarysurgeryinitialobservationsandaproposalforitsstudyinbladdercancer
AT meyerchristian highdoserateintraoperativeradiationtherapyduringhighriskgenitourinarysurgeryinitialobservationsandaproposalforitsstudyinbladdercancer
AT terezakisstephaniea highdoserateintraoperativeradiationtherapyduringhighriskgenitourinarysurgeryinitialobservationsandaproposalforitsstudyinbladdercancer
AT hermanjosephm highdoserateintraoperativeradiationtherapyduringhighriskgenitourinarysurgeryinitialobservationsandaproposalforitsstudyinbladdercancer
AT efronjonathane highdoserateintraoperativeradiationtherapyduringhighriskgenitourinarysurgeryinitialobservationsandaproposalforitsstudyinbladdercancer
AT safarbashar highdoserateintraoperativeradiationtherapyduringhighriskgenitourinarysurgeryinitialobservationsandaproposalforitsstudyinbladdercancer
AT tranphuoct highdoserateintraoperativeradiationtherapyduringhighriskgenitourinarysurgeryinitialobservationsandaproposalforitsstudyinbladdercancer
AT ahujanita highdoserateintraoperativeradiationtherapyduringhighriskgenitourinarysurgeryinitialobservationsandaproposalforitsstudyinbladdercancer
AT pieroraziophillipm highdoserateintraoperativeradiationtherapyduringhighriskgenitourinarysurgeryinitialobservationsandaproposalforitsstudyinbladdercancer
AT bivalacquatrinityj highdoserateintraoperativeradiationtherapyduringhighriskgenitourinarysurgeryinitialobservationsandaproposalforitsstudyinbladdercancer